Particularly, VISTA was described as a potent inhibitory checkpoint on CD68+ macrophages when comparing an immunotherapy-sensitive tumor (melanoma, n = 44) with an immunotherapy-resistant tumor (pancreatic cancer, n = 67) [31]. This evidence concerns the gene VSIR and neoplasm.